中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 自动化研究所
  3. 中国科学院自动化研究所
  4. 中国科学院分子影像重点实验室
Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis

文献类型：期刊论文

作者Sun, Ting2,3; Zhang, Wenjia2,3; Li, Yuan2; Jin, Zhengyu2; Du, Yang1,3; Tian, Jie1,3; Xue, Huadan2
刊名MOLECULAR CANCER THERAPEUTICS
出版日期2020-03-01
卷号19期号:3页码:802-811
ISSN号1535-7163
DOI10.1158/1535-7163.MCT-19-0495
通讯作者Du, Yang(yang.du@ia.ac.cn) ; Tian, Jie(jie.tian@ia.ac.cn) ; Xue, Huadan(bjdanna95@hotmail.com)
英文摘要Postoperative tumor recurrence and metastasis remain an extreme challenge in breast cancer. Therapies that target cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have provided unprecedented clinical benefits in various types of cancer. The aim of this study was to determine whether the combination of anti-CTLA-4 and anti-PD-1 could prevent postoperative breast tumor recurrence and metastasis in breast tumor-bearing mice. 1'he results indicated that the combination of CTLA-4 and PD-1 inhibitors was more effective compared with single inhibitors for mammary tumor growth and prevention of postsurgical tumor recurrence and pulmonary metastasis (P < 0.05), which resulted in prolonged survival (P < 0.05). Analysis of the underlying mechanism revealed that anti-CTLA-4 and anti-PD-1 in combination synergistically promoted the infiltration of CD8+ and CD4+ T cells into tumors (P < 0.05 vs. single inhibitors), thus boosting the antitumor immune responses. In summary, our results revealed that combination immunotherapy with anti-CTLA-4 and anti-PD-1 may present a new, promising regimen to inhibit postoperative breast cancer relapse and lung metastasis and improve patient outcomes, which warrants further investigation in clinical settings.
WOS关键词IMMUNE CHECKPOINT INHIBITORS ; CARCINOMA IN-SITU ; INFILTRATING LYMPHOCYTES ; COMBINED NIVOLUMAB ; ADVERSE EVENTS ; PD-1 BLOCKADE ; CANCER ; SURVIVAL ; PEMBROLIZUMAB ; IPILIMUMAB
资助项目National Key Research and Development Plan of China[2017YFA0205200] ; National Natural Science Foundation of China[81371608] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81227901] ; Beijing Natural Science Foundation[7172170] ; National Public Welfare Basic Scientific Research Project[2017PT32004] ; Chinese Academy of Medical Sciences Students' Innovation Foundation[1007-1002-1-12]
WOS研究方向Oncology
语种英语
WOS记录号WOS:000518190200007
出版者AMER ASSOC CANCER RESEARCH
资助机构National Key Research and Development Plan of China ; National Natural Science Foundation of China ; Beijing Natural Science Foundation ; National Public Welfare Basic Scientific Research Project ; Chinese Academy of Medical Sciences Students' Innovation Foundation
源URL[http://ir.ia.ac.cn/handle/173211/38431]  
专题自动化研究所_中国科学院分子影像重点实验室
通讯作者Du, Yang; Tian, Jie; Xue, Huadan
作者单位1.Univ Chinese Acad Sci, Beijing, Peoples R China
2.Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Radiol, Beijing, Peoples R China
3.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, State Key Lab Management & Control Complex Syst, Beijing, Peoples R China
推荐引用方式
GB/T 7714		 Sun, Ting,Zhang, Wenjia,Li, Yuan,et al. Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis[J]. MOLECULAR CANCER THERAPEUTICS,2020,19(3):802-811.
APA Sun, Ting.,Zhang, Wenjia.,Li, Yuan.,Jin, Zhengyu.,Du, Yang.,...&Xue, Huadan.(2020).Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis.MOLECULAR CANCER THERAPEUTICS,19(3),802-811.
MLA Sun, Ting,et al."Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis".MOLECULAR CANCER THERAPEUTICS 19.3(2020):802-811.

入库方式： OAI收割

来源：自动化研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。